Streetbeat News

Revenues

AXIL

AXIL Brands reported a decrease in Q1 2025 revenue to $5.85M from $6.1M YoY, with a net loss of $109,805 compared to a net income of $154,452 in the prior year. Despite the revenue drop, the company expanded into new channels and increased cash flow.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:12 pm

BNGO

Bionano Genomics has revised its preliminary Q3 revenue guidance downwards from $7.9M-$8.9M to $6.5M-$6.8M, indicating potential challenges in meeting previous revenue expectations.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:03 pm

RTX

RTX's Raytheon has secured a $736 million contract from the US Navy to produce AIM-9X SIDEWINDER missiles, highlighting the company's strong defense sector presence.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 12:02 pm

SITE

SiteOne Landscape Supply (NYSE:SITE) has received mixed analyst ratings over the past three months, with a current average price target of $154.6. Analysts have varied in their ratings, with some maintaining or adjusting their price targets. The company shows strong financial metrics, including a high net margin and ROE, but its revenue growth lags behind industry peers.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:01 pm

ALGN

The article provides an analysis of Align Tech (NASDAQ:ALGN) based on evaluations from six analysts over the past three months. The analysts have mixed views, with most being somewhat bullish. The average 12-month price target has decreased by 6.82% to $314.17. Align Tech's financial performance shows positive revenue growth and strong financial health, but it lags behind industry peers in growth rate.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:01 pm

PAR

In the past three months, 6 analysts have rated PAR Technology (NYSE:PAR), with most being bullish. The average 12-month price target is $62.5, up 11.27% from the previous $56.17. Analysts have raised their price targets, reflecting positive sentiment. PAR Technology shows strong financial health with impressive revenue growth, net margin, ROE, and ROA, but has a higher debt-to-equity ratio than industry averages.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:01 pm

FRSH

Freshworks (NASDAQ:FRSH) has been evaluated by 7 analysts over the past three months, with a mix of bullish and bearish sentiments. The average 12-month price target has decreased by 11.26% to $16.86. Analysts have lowered their price targets, reflecting a cautious outlook. Freshworks shows strong revenue growth but lags behind industry peers, with challenges in ROE and net margin.

Portfolio Pulse from Benzinga Insights

October 10, 2024 | 12:00 pm

PAVM

PAVmed's subsidiary, Veris Health, received a $1.8M grant from the National Institute on Minority Health and Health Disparities to enhance its Veris Cancer Care Platform. This funding will support research over two years.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:56 am

INDV

Indivior's shares are declining following the company's announcement of preliminary Q3 revenue guidance and a reduction in its FY24 net revenue guidance, which is below estimates.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:49 am

TXG

10x Genomics shares fell as the company announced a preliminary Q3 revenue of approximately $151.7 million, marking a 1% decline year over year.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 11:45 am